Vorolanib is primarily used in the treatment of various types of cancers. It functions as an inhibitor of vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR), which are crucial for the growth and maintenance of blood vessels that supply tumors. By blocking these receptors, Vorolanib effectively reduces the blood supply to cancer cells, thereby inhibiting their growth and proliferation. This makes it particularly useful in therapies targeting solid tumors, such as renal cell carcinoma and hepatocellular carcinoma. Additionally, its role in combination therapies is being explored to enhance the efficacy of other anticancer drugs, potentially offering improved outcomes for patients with advanced or treatment-resistant cancers.